Cathaline Pearson
Medical · Las Vegas, NVNPI 1508821281
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 517 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 45 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,824 and has fallen 99.4% since, to $18 in 2025. Among medical clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 517 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$1K
- AstraZeneca$718
- Boehringer Ingelheim$623
- Johnson & Johnson$567
- Lilly USA, LLC$507
- plus $3K from 39 others
What the payments were for
- Food & beverage$8,53699%
- Education$851%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,621 in reported general payments places this provider in the 90th percentile of 250 medical providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 12 | $20,722 |
| JardianceEmpagliflozin | 20 | $18,076 |
| OzempicSemaglutide | 13 | $12,558 |
| FarxigaDapagliflozin Propanediol | 11 | $6,301 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 13 | $540 |
| Levothyroxine Sodium | 39 | $419 |
| Lisinopril | 33 | $415 |
| Losartan Potassium | 27 | $384 |
| Rosuvastatin Calcium | 36 | $365 |
| Atorvastatin Calcium | 50 | $350 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $335 |
| Gabapentin | 17 | $303 |
| Metformin Hcl | 34 | $257 |
| Famotidine | 25 | $237 |
| Metoprolol Succinate | 15 | $201 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $507 | $20,72212 claims |
| Boehringer IngelheimJardiance | $623 | $18,07620 claims |
| Novo NordiskOzempic | $1,135 | $12,55813 claims |
| AstraZenecaFarxiga | $718 | $6,30111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 250 medical providers in Nevada.
Other medical in Las Vegas
- John NotabartoloLas Vegas$284K
- Rachel BowersLas Vegas$29K
- Spencer MeierLas Vegas$24K
- Megan WieselLas Vegas$19K
- Tai PhamLas Vegas$16K
- Eric HilmesLas Vegas$15K
- Wardon OjedapoLas Vegas$12K
- Melchor GochiocoLas Vegas$11K
- Keesha KaplanLas Vegas$11K
- Adelbert WadsworthLas Vegas$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.